Ruxience 500 mg/50mL
rituximab-pvvr · INJECTION, SOLUTION · Pfizer Laboratories Div Pfizer Inc
Ruxience is a prescription injection containing rituximab-pvvr, a CD20-directed antibody used to treat certain blood cancers and autoimmune conditions by targeting specific cells in the immune system. It is administered intravenously and comes as a 500 mg solution.
Key Facts
- Brand Name
- Ruxience
- Generic Name
- rituximab-pvvr
- NDC Code (Product)
0069-0249- Manufacturer
- Pfizer Laboratories Div Pfizer Inc
- Strength
- 500 mg/50mL
- Dosage Form
- INJECTION, SOLUTION
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA761103
- Drug Class
- CD20-directed Cytolytic Antibody [EPC]
- Marketing Start
- 01/23/2020
Recall History
No Recall HistoryFrequently Asked Questions
What is Ruxience used for?
Ruxience is a prescription injection containing rituximab-pvvr, a CD20-directed antibody used to treat certain blood cancers and autoimmune conditions by targeting specific cells in the immune system. It is administered intravenously and comes as a 500 mg solution.
Is Ruxience a controlled substance?
Ruxience is not classified as a controlled substance by the DEA.
What is the generic name for Ruxience?
The generic name for Ruxience is rituximab-pvvr. There are no other listed brand versions of rituximab-pvvr.
What is the NDC code for Ruxience 500 mg/50mL?
The NDC (National Drug Code) for Ruxience 500 mg/50mL is 0069-0249, listed by Pfizer Laboratories Div Pfizer Inc.
Other Ruxience Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)